SLNSilence Therapeutics plc

SLN Stock Price, Valuation & Chart | Silence Therapeutics plc

Compare

$14.790+0.05 (+0.34%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology SLN intrinsic value SLN calculated fair value vs price

Overview Financials Dividends Ratios

SLN Historical price chart

SLN Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization698.59M

PE Ratio-11.55

EPS-1.28

Trading Volume634.20K

Today's High/Low15.28/14.1

Dividend Yield0.00

52 Week High/Low17.58/4.19

Shares Outstanding47.23M

SLN Financial Statement

SLN Analyst ratings

SLN Analysis & performance metrics

SLN Company profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and…

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short…

SLN Management team

Name

Position

Craig A. Tooman M.B.A.CEO

President, Chief Executive Officer & Executive Director

Marie Wikstrom Lindholm Ph.D.

Chief Scientific Officer

Rhonda L. HellumsCFO

Executive Vice President, Chief Financial Officer & Secretary

Barbara A. Ruskin J.D., Ph.D.

Senior Vice President and Chief Intellectual Property & Innovation Officer

J.P. Gabriel

Chief Technical Operations Officer

Eric Floyd M.B.A., M.S., Ph.D.

Senior Vice President of Regulatory Affairs & Quality Assurance

Gem Gokmen Hopkins

Head of IR & Corporate Communications

Curtis Rambaran M.D.

Chief Medical Officer

Name

Position

Craig A. Tooman M.B.A.CEO

President, Chief Executive Officer & Executive Director

Marie Wikstrom Lindholm Ph.D.

Chief Scientific Officer

Rhonda L. HellumsCFO

Executive Vice President, Chief Financial Officer & Secretary

Barbara A. Ruskin J.D., Ph.D.

Senior Vice President and Chief Intellectual Property & Innovation Officer

J.P. Gabriel

Chief Technical Operations Officer

Eric Floyd M.B.A., M.S., Ph.D.

Senior Vice President of Regulatory Affairs & Quality Assurance

Gem Gokmen Hopkins

Head of IR & Corporate Communications

Curtis Rambaran M.D.

Chief Medical Officer

Management Team

Craig A. Tooman M.B.A.CEO

President, Chief Executive Officer & Executive Director

Marie Wikstrom Lindholm Ph.D.

Chief Scientific Officer

Rhonda L. HellumsCFO

Executive Vice President, Chief Financial Officer & Secretary

Barbara A. Ruskin J.D., Ph.D.

Senior Vice President and Chief Intellectual Property & Innovation Officer

J.P. Gabriel

Chief Technical Operations Officer

Eric Floyd M.B.A., M.S., Ph.D.

Senior Vice President of Regulatory Affairs & Quality Assurance

Gem Gokmen Hopkins

Head of IR & Corporate Communications

Curtis Rambaran M.D.

Chief Medical Officer

Management

Craig A. Tooman M.B.A.CEO

President, Chief Executive Officer & Executive Director

Marie Wikstrom Lindholm Ph.D.

Chief Scientific Officer

Rhonda L. HellumsCFO

Executive Vice President, Chief Financial Officer & Secretary

Barbara A. Ruskin J.D., Ph.D.

Senior Vice President and Chief Intellectual Property & Innovation Officer

J.P. Gabriel

Chief Technical Operations Officer

Eric Floyd M.B.A., M.S., Ph.D.

Senior Vice President of Regulatory Affairs & Quality Assurance

Gem Gokmen Hopkins

Head of IR & Corporate Communications

Curtis Rambaran M.D.

Chief Medical Officer

Total 8 executives

SLN Frequently asked questions

What is Silence Therapeutics plc (SLN) Stock Price?

Current stock price of Silence Therapeutics plc (SLN) stock is $14.790. The stock price is +0.34% higher in the session. The intraday range can be seen from this page. Volume of Silence Therapeutics plc (SLN) stock is 634.20K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Silence Therapeutics plc (SLN) stock price going up or down today?

The stock price of Silence Therapeutics plc (SLN) can change with earnings, company news, and overall market sentiment. Silence Therapeutics plc operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Silence Therapeutics plc stock expensive at its current price?

Whether Silence Therapeutics plc looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for SLN on this page is -11.55. EPS on this page is -1.28. Compare those figures with peers and growth expectations before deciding if the current Silence Therapeutics plc price is justified.

How has the stock price of Silence Therapeutics plc (SLN) performed historically?

Historical performance for Silence Therapeutics plc (SLN) is shown on the price chart on this page. Review multi-period moves alongside volume to see how SLN reacted to past earnings and market events.

Should I buy Silence Therapeutics plc (SLN) stock, at this price?

Buying Silence Therapeutics plc (SLN) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.